Strontium ranelate, a therapeutic for osteoporosis, was thought to have a dual mode of action, simultaneously stimulating bone formation and reducing resorption. A recent study casts doubt on this ...

Sept. 26, 2005 (Nashville) -- Strontium ranelate is one of the first drugs to have a dual action that both decreases bone resorption and increases bone formation, according to a study presented here ...

Oct. 29, 2002 (New Orleans) - Strontium ranelate, an investigational drug with a novel mechanism of action against osteoporosis, appears to reduce the incidence of vertebral fractures in ...

As a weapon against osteoporosis, the drug’s beginnings were inauspicious: It was shelved for almost 50 years, and its main component is a mineral widely regarded as nonessential. But the compound ...

SAN DIEGO, CA—Using a new definition of radiological progression, patients with osteoarthritis of the knee treated with strontium ranelate had a significant reduction in such progression, “suggesting ...

As a weapon against osteoporosis, the drug’s beginnings were inauspicious -- it was shelved for almost 50 years, and its main component is a mineral widely regarded as nonessential. But the compound ...

Strontium ranelate—which is approved for the treatment of postmenopausal osteoporosis—has substantial structure-modifying activity and slows the progression of knee osteoarthritis (OA), according to ...

An experimental drug containing strontium makes bones denser and decreases the risk of fractures, a study of elderly women finds. The results add the drug, called strontium ranelate, to a wave of new ...

We recently reported on a study that found encouraging results for patients taking a nutritional supplement called strontium ranelate for knee problems. The supplement is also used by women with ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. An error has occurred. Please try again ...